138 related articles for article (PubMed ID: 35243036)
21. In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases.
Schiff JP; Stowe HB; Price A; Laugeman E; Hatscher C; Hugo GD; Badiyan SN; Kim H; Robinson CG; Henke LE
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):1022-1031. PubMed ID: 35768023
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma.
Poel R; Stuessi Lobmaier A; Andratschke N; Unkelbach J; Tanadini-Lang S; Guckenberger M; Foerster R
Br J Radiol; 2019 Aug; 92(1100):20190113. PubMed ID: 31264474
[TBL] [Abstract][Full Text] [Related]
23. Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation.
Jouglar E; Wagner A; Delpon G; Campion L; Meingan P; Bernier V; Demoor-Goldschmidt C; Mahé MA; Lacornerie T; Supiot S
PLoS One; 2016; 11(10):e0164643. PubMed ID: 27764132
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar.
Mazzarotto R; Simoni N; Guariglia S; Rossi G; Micera R; De Robertis R; Pierelli A; Zivelonghi E; Malleo G; Paiella S; Salvia R; Cavedon C; Milella M; Bassi C
Front Oncol; 2020; 10():600940. PubMed ID: 33392093
[TBL] [Abstract][Full Text] [Related]
25. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
26. Simulated daily plan adaptation for magnetic resonance-guided liver stereotactic body radiotherapy.
Taylor E; Lukovic J; Velec M; Shessel A; Stanescu T; Dawson L; Létourneau D; Lindsay P
Acta Oncol; 2021 Feb; 60(2):260-266. PubMed ID: 33170058
[TBL] [Abstract][Full Text] [Related]
27. Initial Evaluation of a Novel Cone-Beam CT-Based Semi-Automated Online Adaptive Radiotherapy System for Head and Neck Cancer Treatment - A Timing and Automation Quality Study.
Yoon SW; Lin H; Alonso-Basanta M; Anderson N; Apinorasethkul O; Cooper K; Dong L; Kempsey B; Marcel J; Metz J; Scheuermann R; Li T
Cureus; 2020 Aug; 12(8):e9660. PubMed ID: 32923257
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
29. Dosimetric comparison between proton beam therapy, intensity modulated radiation therapy, and 3D conformal therapy for soft tissue extremity sarcoma.
Laughlin BS; Golafshar M; Prince M; Liu W; Kutyreff CJ; Ahmed SK; Vern Gross TZ; Haddock M; Petersen I; DeWees TA; Ashman JB
Acta Oncol; 2023 May; 62(5):473-479. PubMed ID: 37154167
[TBL] [Abstract][Full Text] [Related]
30. CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer.
Waters M; Price A; Laugeman E; Henke L; Hugo G; Stowe H; Andruska N; Brenneman R; Hao Y; Green O; Robinson C; Gay H; Michalski J; Baumann BC
Clin Transl Radiat Oncol; 2024 Jan; 44():100693. PubMed ID: 38021093
[TBL] [Abstract][Full Text] [Related]
31. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.
Chi A; Ma P; Fu G; Hobbs G; Welsh JS; Nguyen NP; Jang SY; Dai J; Jin J; Komaki R
PLoS One; 2013; 8(4):e59729. PubMed ID: 23577071
[TBL] [Abstract][Full Text] [Related]
32. In Silico Single-Fraction Stereotactic Ablative Radiation Therapy for the Treatment of Thoracic and Abdominal Oligometastatic Disease With Online Adaptive Magnetic Resonance Guidance.
Lee S; Yadav P; van der Kogel AJ; Bayouth J; Bassetti MF
Adv Radiat Oncol; 2021; 6(3):100652. PubMed ID: 34195490
[TBL] [Abstract][Full Text] [Related]
33. A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain.
Ranger A; Dunlop A; Hutchinson K; Convery H; Maclennan MK; Chantler H; Twyman N; Rose C; McQuaid D; Amos RA; Griffin C; deSouza NM; Donovan E; Harris E; Coles CE; Kirby A
Clin Oncol (R Coll Radiol); 2018 Jun; 30(6):346-353. PubMed ID: 29483041
[TBL] [Abstract][Full Text] [Related]
34. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases.
Palacios MA; Bohoudi O; Bruynzeel AME; van Sörsen de Koste JR; Cobussen P; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):426-433. PubMed ID: 29902559
[TBL] [Abstract][Full Text] [Related]
35. Investigation of Isotoxic Dose Escalation and Plan Quality with TDABC Analysis on a 0.35 T MR-Linac (MRL) System in Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy (MRgRT) for Primary Pancreatic Cancer.
Hawranko R; Sohn JJ; Neiderer K; Bump E; Harris T; Fields EC; Weiss E; Song WY
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566712
[TBL] [Abstract][Full Text] [Related]
36. Proton Beam Therapy for Locally Advanced Head and Neck Tumors: An Analysis of Dosimetric and Clinical Outcomes.
Sheikh S; Kharouta MZ; Pidikiti R; Damico NJ; Choi S; Dorth JA; Mansur DB; Machtay MX; Yao M; Bhatt AD
Am J Clin Oncol; 2022 Feb; 45(2):81-87. PubMed ID: 35073281
[TBL] [Abstract][Full Text] [Related]
37. Range modulation in proton therapy planning: a simple method for mitigating effects of increased relative biological effectiveness at the end-of-range of clinical proton beams.
Buchsbaum JC; McDonald MW; Johnstone PA; Hoene T; Mendonca M; Cheng CW; Das IJ; McMullen KP; Wolanski MR
Radiat Oncol; 2014 Jan; 9():2. PubMed ID: 24383792
[TBL] [Abstract][Full Text] [Related]
38. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
39. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
40. Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review.
Murray LJ; Lilley J; Hawkins MA; Henry AM; Dickinson P; Sebag-Montefiore D
Radiother Oncol; 2017 Nov; 125(2):213-222. PubMed ID: 29066125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
